Glucagon and GLP-1 receptor co-agonist
Cotadutide 100 ug subcutaneous once daily
COTA_SC_100UG_QD
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.64 (-1.17 to -0.12) | 0.31 |
| Type 2 diabetes (adults) | HbA1c change | weeks 36 to 64 (target week 52) | Placebo | MD -0.51 (-0.85 to -0.18) | 0.75 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 36 to 64 (target week 52) | Placebo | MD -1.91 (-3.80 to 0.32) | 0.60 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD -1.47 (-3.28 to 0.33) | 0.66 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 3.00 (1.15 to 7.19) | 0.36 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 20 to 40 (target week 26) | Placebo | MD -1.90 (-6.85 to 3.63) | 0.42 |
| Type 2 diabetes (adults) | Percent body weight change | weeks 40 to 104 (target week 68) | Placebo | MD -1.88 (-7.87 to 5.44) | 0.56 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 40 to 104 (target week 68) | Placebo | OR 4.21 (1.18 to 11.53) | 0.64 |
| Type 2 diabetes (adults) | Weight loss of 5 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 3.18 (0.91 to 9.04) | 0.42 |
| Type 2 diabetes (adults) | Weight loss of 10 percent or more | weeks 20 to 40 (target week 26) | Placebo | OR 3.99 (0.69 to 23.60) | 0.37 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.18 (0.56 to 2.47) | 0.40 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 4.74 (1.86 to 12.18) | 0.19 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 3.61 (1.83 to 6.85) | 0.38 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 4.21 (1.62 to 10.67) | 0.36 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 3.15 (1.43 to 6.93) | 0.23 |
| Type 2 diabetes (adults) | Constipation | longest follow-up | Placebo | HR 0.58 (0.04 to 3.37) | 0.75 |